Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shenzhen Dehe Biotechnology

Request full access

DeHe Biotech is a Healthcare company

ChinaFounded 2016Biotech & Life Sciences

About Shenzhen Dehe Biotechnology

Established in May 2016, Shenzhen Dehe Biotechnology Co., Ltd. operates as a global supplier of high-value microalgae raw materials, with a strategic focus on industrial-scale intelligent cultivation. The company was co-founded by Cai Minghan, who serves as General Manager, and John Rooymans, the Chief Scientist. The leadership team also includes Chairman Jiao Jian. Dehe Biotech's inception followed years of foundational work, including the invention of spectral power distribution (SPD) technology in Europe by John Rooymans in 2006 and the establishment of a microalgae-specific growth light engine laboratory in the Netherlands in 2010. A significant milestone was achieved in 2015 when the Haematococcus Pluvialis artificial light industrial cultivation laboratory was relocated from the Netherlands to Shenzhen, China.

Dehe Biotechnology's core business revolves around the cultivation and processing of microalgae to produce high-value ingredients, primarily natural astaxanthin. The company employs a B2B model, supplying these raw materials to a diverse client base across the pharmaceutical, nutritional supplement, cosmetics, and functional food industries. A key aspect of their operational strategy is the use of proprietary technology that replaces natural sunlight with artificial light sources, enabling a fully sealed, industrialized, and automated cultivation process. This method addresses supply chain issues and ensures a consistent, high-quality output. The company has established a comprehensive industrial chain with multiple subsidiaries, including a research and development center in Shanghai and production bases in Anhui and Xinjiang, each serving a distinct purpose from R&D to manufacturing for specific markets.

The company's flagship product is natural astaxanthin, a powerful antioxidant derived from Haematococcus pluvialis microalgae. This product is offered in various forms, including oleoresin, powder, and water-soluble emulsions, to meet the needs of different applications. Dehe Biotech also produces other microalgae extracts like Fucoxanthin. The firm's products are marketed under brands such as AstaKINGTM and FucoxMit®, with a significant portion of sales, reportedly as high as 90%, coming from overseas markets in Southeast Asia, Europe, and North America. The company has successfully secured multiple rounds of funding, including an A-round in 2018, a B-round in July 2023, and a strategic plus-round in December 2023, to finance the construction of new production facilities and enhance research and development capabilities.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
21.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Dec 2023 $2.8M $38M Tai Ling Holdings ↗
SERIES B✓Equity / VC Jul 2023 $2.8M $38M Fupeng Assets ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Shenzhen Dehe Biotechnology website traffic

Latest recorded traffic for Shenzhen Dehe Biotechnology is 630 monthly website visits, up 31.3% over the last three months. Shenzhen Dehe Biotechnology's team grew 0% over the past year.

Latest monthly visits630 3-month web change+31.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shenzhen Dehe Biotechnology in its local ecosystem

Live from Dealroom

The Shenzhen Dehe Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Fupeng Assets
  • Tai Ling Holdings
Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shenzhen Dehe Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shenzhen Dehe Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.